Linagliptin: Phase III data

In a double-blind Phase III trial in 245 patients with inadequately controlled Type II diabetes, once-daily 5 mg oral linagliptin as an add-on to sulfonylurea met the

Read the full 276 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE